Background. Chronic kidney disease (CKD) has a high prevalence in pregnancy. In a period of cost constraints, there is the need for identification of the risk pattern and for follow-up. Methods. Patients were staged according to K-DOQI guidelines. The analysis was prospective, January 2000-June 2011. Two hundred and forty-nine pregnancies were observed in 225 CKD patients; 176 singleton deliveries were recorded. The largest group encompasses stage 1 CKD patients, with normal renal function, in which 127 singleton deliveries were recorded. No hard outcomes occurred (death; dialysis); therefore, surrogate outcomes were analysed [caesarean section, prematurity, need for neonatal intensive care unit (NICU)]. Stage 1 patients were compared with normal controls (267 low-risk pregnancies followed in the same setting) and with patients with CKD stages 2-4 (49 singleton deliveries); two referral patterns were also analysed (known diagnoses; new diagnoses). Results. The risk for adverse pregnancy rises significantly in stage 1 CKD, when compared with controls: odds ratios were caesarean section 2.73 (1.72-4.33); preterm delivery 8.50 (4.11-17.57); NICU 16.10 (4.42-58.66). The risks rise in later stages. There is a high prevalence of new CKD diagnosis (overall: 38.6%; stage 1: 43.3%); no significant outcome difference was found across the referral patterns. Hypertension and proteinuria are confirmed as independent risk factors. Conclusions. CKD is a risk factor in pregnancy; all patients should be followed within dedicated programmes from stage 1. There is need for dedicated interventions and educational programmes for maximizing the diagnostic and therapeutic potentials in early CKD stages.
Introduction
Chronic kidney disease (CKD) is a growing and often undiagnosed health care problem; its full dimension has only recently been acknowledged because of its wider definition and the frequent lack of symptoms [1] . The redefinition of CKD focuses attention on the earlier, usually asymptomatic, stages of the disease [2] . The CKD staging and definition system is undergoing extensive criticism, in particular in the elderly, due to the risk of over-diagnosis of CKD [3] . However, in younger individuals, the risks of over-diagnosis of CKD are counterbalanced by the advantages of early interventions. According to the present broad disease definitions, it has been calculated that the prevalence of CKD may reach 3% in women of childbearing age [4, 5] . However, the prevalence of CKD is still often underappreciated in pregnancy, few settings offer an integrated nephrological and obstetric follow-up and a systematic approach to the early diagnosis of CKD is not yet part of the routine follow-up of pregnant women.
There are at least two reasons that may impair an early diagnosis of CKD in pregnancy: the physiological increase in the renal clearances from the early stages of pregnancy and the clinical and laboratory overlap with pre-eclampsia (PE). In fact, PE shares the presence of proteinuria and hypertension with several forms of CKD [6, 7] . Conversely, the relationship between PE and CKD is far from being completely known [8] .
CKD is a relevant outcome modifier in pregnancy. Even though the outcome has improved over the last decades, recent studies, including a previous one from our group, show increased materno-fetal morbidity starting from the first CKD stages [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Overall, the risk of negative materno-fetal outcomes is inversely related to renal function and is increased in the presence of baseline proteinuria and hypertension and in systemic diseases [19] [20] [21] [22] .
The wider recognition of the impact of early-stage CKD on pregnancy outcomes could have a strong organizational and economic impact on the health care system, requiring integrated teams and dedicated structures, a difficult task at a time of substantial cost constraints.
Therefore, the present study was aimed at analysing the outcomes of pregnancy in a large cohort of women referred to a tertiary care setting for the presence of CKD, with particular attention to the cases with normal renal function. As the great heterogeneity of kidney diseases did not allow stratification according to the different diagnoses, the patients were stratified according to the CKD stage and, for the largest subset of CKD stage 1, according to referral pattern, dividing the patients into two main categories: 'know diagnoses' and 'new diagnoses'.
The availability of both a 'low-risk' group and a of patients in more advanced CKD stages allows definition of the risks and contextualization of the results, facilitating comparison with data reported in other settings, more often regarding the late CKD stages [10] [11] [12] [14] [15] [16] [17] [18] [19] .
The study may add information for the planning of interventions aimed at improving pregnancy-related outcomes in CKD women.
Materials and methods

Study setting and inclusion criteria
The study was conducted in the Maternoetal Medicine Unit of Sant'Anna University Hospital (150 beds for obstetric patients) in Turin, Italy [9] . From 2000, all patients referred with kidney disease were followed by the same obstetric and nephrological team (from 2002 in a dedicated outpatient unit). Main baseline and outcome data were gathered prospectively from the start of the activity. The patients were referred from different nephrology units and regional prenatal care centres and, since 2007, from general physicians.
PE and Hemolysis, Elevated Liver enzymes, Low Platelet (HELLP) syndrome are routinely managed by the obstetricians of the MaternoFetal Unit. They are not referred to our unit unless there is the need for differential diagnosis with CKD; these were identified as 'other/PE', and not included in the present series.
Patient and control population
In total, 249 pregnancies were observed in 225 women with CKD (1 January 2000-30 June 2011): 18 women had 2 pregnancies; 3 women had 3 pregnancies. Referrals to the unit increased since the reorganization in 2009, and possibly as an effect of the publication of our previous results regarding 120 pregnancies and 91 singleton deliveries in the period January 2000-May 2009 [9] (Figure 1) .
The study included all patients referred to the Outpatient Unit or admitted to the Obstetrics Ward who had a diagnosis of CKD before or during pregnancy. In the present study, each pregnancy was considered a separate 'case'. The patients lost to follow-up (three cases), ongoing pregnancies (27 singletons, 1 twin pregnancy), twin deliveries [13] , miscarriages [17] and pregnancy terminations [12] were excluded, thus leaving 176 singleton deliveries for the statistical analysis.
The historical control group of 'low-risk pregnancies' gathered in 1999-2007 was employed for comparison. The control group consisted of a cohort of 297 singleton low-risk pregnancies cared for in the same Materno-Fetal Unit, as described elsewhere [9] . The type of care was felt to be more important than a precise age and ethnicity match; therefore, all patients were included and the differences for age and ethnicity (singleton delivery: 29 versus 30 years and 77 versus 87% non-Caucasians) were not considered as clinically relevant [9] .
The following data were considered in all patients: age, parity, race, week of the first visit, educational level, body mass index (BMI), number of admissions, gestational age at delivery, type of delivery, clinical complications in the mother, fetal weight, Apgar index, sex, admission to Intensive Care Unite, outcome; for the pathological pregnancies, CKD stage, serum creatinine, proteinuria, kidney disease, previous follow-up, referral to the unit were recorded.
Definitions employed GFR measurement. CKD was classified according to K-DOQI guidelines [2, 4] . The most widely used formulae (Cockcroft and Gault, MDRD and Epidemiology Collaboration (EPI)) have important limits or are not validated in pregnancy; thus, glomerular filtration rate (GFR) calculation was based on preconception data, when available within 3 months prior to conception [23] [24] [25] . When the preconception data were not available, data at first control in pregnancy were used, possibly leading to underestimation of the severity of kidney disease due to the physiological decrease of serum creatinine during pregnancy [2, 4, [23] [24] [25] . The Cockcroft and Gault formula was chosen because of the adjustment for weight, partially accounting for underweight or obesity, both of which are represented in our population. We also applied the MDRD and EPI formulae, controlling for cases that would have been classified otherwise. After referral, creatinine clearance calculated on 24-h urine collection was considered as approximating GFR. Proteinuria was assessed on 24-h urine collection.
Diagnostic categories. The patients were stratified into two main diagnostic referral categories: patients in whom the diagnosis of CKD was known and identified as a risk factor for pregnancy (known diagnoses); patients in whom the diagnosis of CKD was either made in pregnancy or in whom the diagnosis of CKD was known but not identified as a risk factor for pregnancy (new diagnoses). The patients with known diagnoses are referred by nephrology teams, and the new ones are by definition first seen by a nephrologist during pregnancy, and are usually referred by the obstetrical teams.
Obstetric definitions. Hypertension was defined as systolic blood pressure ≥140 and/or diastolic blood pressure ≥90, or anti-hypertensive therapy; patients on anti-hypertensive therapy prior to conception were included even when anti-hypertensive therapy was discontinued in pregnancy.
PE was strictly defined as hypertension accompanied by proteinuria ≥300 mg/24 h after 20 weeks of gestational age in a previously normotensive, non-proteinuric woman, in the absence of other signs or symptoms indicating a different nephrological diagnosis; the presence of Doppler flow alterations was considered to support a PE diagnosis [26] . This diagnosis applied only to women who were normotensive and nonproteinuric at referral and during the first 20 gestational weeks (for example, affected by a glomerulonephritis (GN) in full remission, or by pyelonephritic kidney scars); since the definition of 'superimposed PE' (that is PE superimposed either on hypertension or on proteinuria already present at baseline) is not unequivocal and the overlap with CKD is higher, we did not employ it in this study.
A newborn was defined as small for gestational age (SGA) when the birthweight was below the 10th centile according to Italian birthweight references [27, 28] . Preterm delivery was defined as delivery before 37 completed weeks of gestational age; a further analysis was performed for 'early' preterm deliveries, defined as deliveries before 34 completed weeks [29] .
Prenatal and intrapartum care. Prenatal and intrapartum care of lowrisk pregnancies followed the current guidelines [9, 27, 30] . The frequency of nephrological and obstetric control visits for CKD patients was individualized (weekly-monthly).
On each clinical consultation, the blood pressure was measured at least once and weight was recorded; fetal growth was controlled by serial measurements of symphysis fundus height. Ultrasound biometry and Doppler study of uterine and umbilical arteries were individualized. In patients at risk for proteinuria and urinary infections, urinalysis and urine cultures were performed weekly or every two weeks. In pyelonephritis, stone disease, reflux nephropathy and other malformations, ultrasounds of the mother's kidneys were scheduled every 3 months.
The blood pressure therapeutic goal was ≤130/80. Drugs of choice were nifedipine or α-methyldopa, the latter preferred in the case of intense proteinuria or peripheral oedema. Beta blockers or doxazosine were employed in the case of insufficient response or severe side effects with the above drugs. All patients were instructed to measure blood pressure at home (in hypertensive cases, 2-3 measurements/day).
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urinalysis and urinary culture, serum electrolytes, coagulation and blood cell counts; other laboratory tests were on demand. Hospitalization was required in the presence of poorly controlled hypertension, worsening of renal function, proteinuria of new onset or with rapid worsening, severe upper urinary tract infection and for any other problem of the mother and/or fetus.
In singletons, the aim was to delay delivery at least until 36 weeks; indications for early delivery were severe worsening of maternal and/or fetal conditions until 32 weeks of gestational age or less severe worsening after 32 weeks. In addition to the classic hallmarks of PE or HELLP syndrome, worsening of the maternal conditions included poorly controlled hypertension, rapidly increasing nephrotic proteinuria, rapid increase in serum creatinine, alone or in combination. Fetal worsening included abnormal fetal heart rate tracings at any gestational age, absent end diastolic flow velocities at Doppler study of the umbilical arteries at or after 32 weeks of gestational age, no fetal growth over two weeks at later gestational ages. In these cases, betamethasone for induction of lung maturation was routinely administered at standard doses. Caesarean section was performed for fetal indications, before or during labour, or in cases of unfavourable conditions or lack of response to induction. The main indications for admission to the Neonatal Intensive Care Unit (NICU) were birthweight <1500 g, gestational age <34 weeks, Apgar score below 7 at 5′, need for intubation.
Statistical analysis
The data were collected prospectively and periodically entered into the electronic database; start of observation: referral to the unit; end of observation: 1 month after delivery. Since no maternal or fetal deaths were observed in the singleton cohort and none of the patients needed dialysis during pregnancy or in the first month after delivery, we limited our analysis to the following surrogate outcomes: preterm delivery (<37 and <34 weeks), SGA baby, admission to the NICU, Caesarean section.
Common parameters were analysed in CKD patients in comparison with the control group of 'low-risk pregnancies'; these analyses included referral to the unit before or after 12 weeks of gestational age; maternal age, dichotomized at the median; parity ( primiparous versus other); educational level ( primary school versus others); race (Caucasian versus others).
As for the CKD cohort, the analysis took into account the CKD stage and referral pattern, the presence of hypertension and the presence and level of proteinuria (<300 mg/day; 300 mg to <1 g/day; ≥1 g/day).
The following groups were considered as reference: CKD stage 1 versus other stages; known diagnosis versus other diagnostic patterns; proteinuria <0.3 versus other levels; no hypertension versus hypertension. A descriptive analysis was performed as appropriate (mean and standard deviation for parametric data; median and range for nonparametric data). Paired t-test, chi-square test, Fisher's test, KruskalWallis test, Mann-Whitney U-test, ANOVA and t-test with Bonferroni were used for comparisons between cases and controls and among groups. Significance was set at <0.05. Multivariate logistic regression analysis was used to control for simultaneous effects of covariates. Adjusted odds ratio (OR) and 95% confidence intervals were derived from the estimated regression coefficients. Statistical analyses were performed with SPSS vers18.0 for Windows (SPSS, Chicago, IL, USA) [31] .
Results
Baseline data
The baseline data are reported in Table 1 for all patients and for singleton deliveries, in order to control for attrition biases. No significant difference was found, suggesting no or irrelevant attrition bias.
The largest subset of the study population is represented by patients with normal renal function: 127 singleton deliveries in stage 1 CKD patients.
No significant demographic baseline difference was found across CKD stages; as expected by definition, the prevalence of hypertension, proteinuria and median creatinine and GFR levels are different ( Table 2 ). The lower prevalence of the late CKD stages reflects the distribution of CKD stages in the overall population in a setting of systematic recruitment of CKD patients. No case on dialysis was referred.
Overall, 19 miscarriages and 13 pregnancy terminations were recorded. Two patients terminated pregnancy by their own volition; in two cases, the decision reflected both a high clinical risk and personal preferences (nephrotic syndrome, later diagnosed as membranous nephropathy, and stage 4 CKD patient, both without family support). Pregnancy termination was decided for clinical reasons in eight cases: fetal malformations (four cases), severe early PE (three cases, who were by definition neither hypertensive nor proteinuric during the first gestational weeks), while in one case, worsening of renal function played a role, supporting the choice to terminate pregnancy in the setting of severe intrauterine growth restriction and severe pregnancy-induced hypertension. Univariate outcome analysis: CKD stage 1 versus controls and CKD stages 2-4. Table 3 reports the main materno-fetal outcomes in CKD patients and in controls; of note, the differences between CKD stage 1 and controls are significant for all the tested outcomes except SGA, a parameter influenced by the policy of delivery in the presence of flattening of the growth curve; thus, a lower prevalence of SGA may reflect a policy of early delivery. The trends across stages suggest a continuous increase of risk for adverse outcomes in parallel to the decreasing kidney function. The differences between stage 1 and stages 2-4 are significant for all the tested outcomes, except for SGA, even if a trend towards increase in prevalence of SGA is observed; the comparison between stage 1 and stage 2 CKD reaches statistical significance as for gestational age and birthweight (Table 3) . Table 4 reports the changes in renal function and proteinuria in the different stages, from referral to delivery in a subset of 127 CKD cases referred before the 20th week of gestation.
In the large subset of CKD stage 1 cases (89 patients referred before the 20th gestational week), proteinuria significantly increases, although the data are very scattered, as shown by the wide ranges and the median value remains in a 'normal' range; creatinine data show a small increasing trend throughout pregnancy; only one patient (type 1 diabetic, stage 2 CKD at the start of pregnancy) doubled serum creatinine during gestation.
PE superimposed on CKD was diagnosed in 6 cases, 3 of which underwent pregnancy termination before the 23rd gestational week; hence, the prevalence is 6/188 (3.2%) considering the 176 singleton deliveries, plus the 12 pregnancy terminations, occurred after the 12th week. The incidence of PE was 1.1% in our low-risk control population, in line with the literature data obtained in lowrisk patients, such as kidney transplant donors [9, [32] [33] [34] .
Univariate analysis: stage 1 CKD patients according to referral patterns Table 5 reports the univariate analysis regarding the main materno-fetal short-term outcomes in the subset of stage 1 CKD patients (127 singleton deliveries), with patients sorted according to the two main referral patterns (known and new diagnoses).
In keeping with the results obtained in the overall stage 1 CKD population (Table 3 ), the differences between CKD patients and the controls are significant for most of the tested outcomes in all subsets (SGA being confirmed as the exception), without significant differences between known and new diagnoses (Table 5) . Table 6 shows the multivariate logistic regression analysis between CKD stage 1 patients and controls. The analysis confirms a highly significant effect of being in the CKD stage 1 cohort for all the tested outcomes. The relative risk of being affected by stage 1 CKD ranges from 2.73 for caesarean section, to 8.50 for preterm delivery (<37 completed gestational weeks). There is also a mild protective effect for Caucasian race and an increase in OR for prematurity in older women, similar to that observed in the overall population. Table 7 reports the risks of later stages of CKD versus stage 1: the OR for caesarean section is not significant, while the OR preterm delivery and for the need for NICU significantly rises in the subsequent CKD stages (2.84 for preterm delivery and 2.59 for the need for NICU).
Multivariate logistic regression analysis
Hypertension and proteinuria are confirmed as relevant risk factors: statistical significance is reached in the first case for caesarean section and preterm, or early preterm 
Discussion
The broader definition of CKD, according to the K-DOQI guidelines, is leading to the recognition of an increasing number of cases with early CKD in several settings, including pregnancy [1, 2, 4, 5] . At this time of cost constraints, the recognition of increasing needs may be seen as an unbearable challenge for the health care system. In our setting, one of the first Italian outpatient units dedicated to pregnancy and kidney diseases, referrals doubled in the last 2 years (in 2000-2009: 120 pregnancies referred, 110 in CKD patients; in 2009-2011: 158 referred, 137 in CKD patients) [9] . This led to a re-analysis of our population to try to answer the question whether we should follow all cases and for which specific risks. One of the characteristics of our cohort is the high prevalence of CKD patients with normal renal function (127 singleton deliveries in CKD stage 1 patients). From a health care point of view, this is an interesting cohort, both because the prevalence of CKD stage 1 was calculated as high as 3% of pregnancies, and because stage 1 CKD patients were less studied as for pregnancy outcomes, particularly in the past when CKD was considered synonymous with decreased kidney function or severe proteinuria [4, 35, 36] .
Thus, the analysis was focussed on CKD stage 1 patients, both in comparison with a cohort of 267 lowrisk pregnancies and with 49 patients in later CKD stages, followed in the same setting.
In an attempt to identify specific subsets of patients, on whom tailoring dedicated interventions, the stage 1 Odds ratio and 95% confidence interval. patients were also stratified according to referral for known or new CKD diagnosis.
The main results of our study can be summarized in two main points:
The first one is in regard to the overall cohort of CKD stage 1 patients. The present study confirms on a larger scale the previous experience of our group, further supporting that stage 1 CKD patients are at increased risk for adverse pregnancy outcomes, with an OR ranging from 2.7 for Caesarean section to 8.50 for preterm delivery and 16.10 for need for NICU (Table 6 ) [9] . These data are in line with a growing body of literature data [32, 33, [37] [38] [39] ( Tables 2, 3 and 6) .
The risk for adverse pregnancy-related events increases along with the CKD stage. In our population, being in stage 2-4 CKD increases the OR by about 2, for preterm delivery and need for NICU, when compared with stage 1 CKD ( Table 7) . Even though a lack of a common language still prevents a precise contextualization, our results compare favourably with the recent literature, mainly obtained in later CKD stages [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [40] [41] [42] .
In contrast to our previous study, in which the results recorded in stage 1 and stage 2 CKD were almost equal, the stepwise increase along stages is more clear and statistical difference is reached between stage 1 and 2 CKD as for birthweight and gestational age, underlining the importance of an even 'minor' decrease in kidney function (Tables 2 and 6 ) [9] .
The second point is in regard to an attempt to analyse CKD stage 1 patients according to diagnostic pattern. The prevalence of new diagnosis was high (over 40% in stage 1), underlying the importance of pregnancy as a valuable occasion for early diagnosis of CKD and for specific interventions (Table 2) .
No difference was found between new and known diagnoses, confirming hypertension and proteinuria as adjunctive risk factors for adverse pregnancy-related outcomes, and underlining that until multi-centre cohort studies will allow precise stratification according to the different kidney diseases, all CKD patients should be considered at risk for pregnancy-induced complications (Tables 5 and 7 ) [40] [41] [42] .
Two practical suggestions can be derived from this analysis: first, kidney function data, including at least creatinine, electrolytes and urinalysis and, if possible, kidney ultrasounds, should be performed to timely identify patients with pre-existing kidney diseases; secondly, educational interventions should stress the importance of interstitial nephropathies and of kidney malformations, including pyelonephritis scars and single kidney, as they share with the better-known glomerular nephropathies, an increased risk of adverse pregnancy-related events (Table 5) .
Our study has weaknesses and strengths, in part common to clinical studies on CKD and pregnancy. One of the limits is heterogeneity of disease, with a frequent lack of preconception data, thus impairing precise staging of CKD at the start. The assessment of renal function in pregnancy remains a challenge, as all the established formulas display important limits in pregnancy; we continued with our working choice of the Cockcroft-Gault formula, applying it whenever possible to preconception data, while being aware of the limits of both the formula and the CKD staging in pregnancy [3, 9, [23] [24] [25] 40] .
One of the strengths of our study is the availability of a 'low-risk' control population with the same follow-up.
A second strength is the very low incidence of loss to follow-up in the study group (three cases) and in the control group, assuring against attrition biases after referral. A third one is the same nephrological and obstetric team from the beginning, ensuring continuity and a relatively homogeneous approach (even with the obvious changes and improvements over time) in a field such as pregnancy in which differences among centres are very important.
In a new and developing field, nothing is trivial; our results, which favourably compare with the recent literature, reflect a combination of underlying kidney disease and intervention which may impact on the outcome; for example, the surrogate outcome of caesarean section is linked with preterm delivery and may reflect a more aggressive policy towards the preservation of maternal kidney function. Such a policy may be possible only in settings, such as ours, where an excellent neonatology ward is present, and only multicentre studies will shed light on the role of the different factors that influence outcome. Furthermore, a referral bias cannot be excluded, leading to referral of pregnant women with the more severe manifestations to the specialized Unit.
Even if a detailed discussion goes far beyond the aim of the present study, a further practical suggestion can be derived from our experience: as morbidity is mostly related to prematurity, referral to a tertiary care centre, with skilled neonatologists, is a key for success. The fact that, despite our efforts, the prognosis is still different from that of the control population underlines the need for interventional studies in this delicate context.
Conclusions
Our data indicate an increased risk for adverse pregnancyrelated morbidity in all CKD patients in all stages, starting form CKD stage 1. Even minor differences in kidney function (stage 2 versus stage 1) increase the risk for adverse pregnancy-related outcomes.
Within the limits of each context-sensitive analysis, our study supports a dedicated follow-up programme for pregnant women, starting from stage 1 CKD. Only a broader, multi-centre study, allowing stratification for specific diseases, will allow more precise tailoring of diagnostic and management protocols.
